Expression analysis of liver-specific circulating microRNAs in HCV-induced hepatocellular Carcinoma in Egyptian patients

Theodor Bilharz Research Institute

Bibliographic Information

Authors: Mourad L.; El-Ahwany E.; Zoheiry M.; Abu-Taleb H.; Hassan M.; Ouf A.; Rahim A.A.; Hassanien M.; Zada S.

Journal: Cancer Biology and Therapy

Publisher: Taylor and Francis Inc.

Publication Date: 16 February 2018

Volume / Issue: Volume 19 / Issue 5

Pages: 400–406

ISSN: 15384047

DOI: 10.1080/15384047.2018.1423922

Scopus: View on Scopus

PubMed: 29333940

Document Type: Article

Access: All Open Access; Green Open Access; Hybrid Gold Open Access


Authors and Affiliations

Mourad L., Biology Department, American University in Cairo, Cairo, Egypt; El-Ahwany E., Immunology Department, Theodor Bilharz Research Institute, Giza, Egypt; Zoheiry M., Immunology Department, Theodor Bilharz Research Institute, Giza, Egypt; Abu-Taleb H., Environmental Department, Theodor Bilharz Research Institute, Giza, Egypt; Hassan M., Immunology Department, Theodor Bilharz Research Institute, Giza, Egypt; Ouf A., Biology Department, American University in Cairo, Cairo, Egypt; Rahim A.A., Hepato-Gastroenterology Department, Theodor Bilharz Research Institute, Giza, Egypt; Hassanien M., Hepato-Gastroenterology Department, Theodor Bilharz Research Institute, Giza, Egypt; Zada S., Biology Department, American University in Cairo, Cairo, Egypt


Abstract

Objectives: Due to the absence of reliable and accurate biomarkers for the early detection of liver malignancy, circulating microRNAs have recently emerged as great candidates for prompt cancer identification. Therefore, the aim of this study was to investigate the potential of liver-specific circulating microRNAs as an accurate non-invasive diagnostic tool for early diagnosis of hepatitis C virus (HCV)-induced hepatocellular carcinoma (HCC). Methodology: A total of 165 patients were enrolled in this study and categorized into four main groups: 42 chronic hepatitis C (CHC) without cirrhosis, 45 CHC with cirrhosis (LC), 38 HCC with HCV patients, and 40 healthy controls. The expression profiles of seven miRNAs (miR-16, miR-34a, miR-125a, miR-139, miR-145, miR-199a, and miR-221) were analyzed using real-time PCR. Results: Serum levels of miRNA-125a, miRNA-139, miRNA-145, and miRNA199a were significantly lower (p < 0.01) in HCC than in both CHC and LC groups. On the other hand, no significant difference was shown in the expression of miR-16, miR-34a, and miR-221 between the CHC, LC, and HCC groups. MiR-16, miR-34a, and miR-221 were significantly elevated in the HCC group compared to the control group. MiR-34a showed the highest specificity and sensitivity. Conclusions: The results indicated that the measurement of serum levels of miR-125a, miR-139, miR-145, and miR-199a can help to differentiate HCC from CHC and LC. Also, miR-16, miR-34a, and miR-221 serum levels would have a prognostic value. MiR-34a had the highest specificity and sensitivity, indicating that it might serve as a novel and potential non-invasive biomarker for HCV-induced HCC. © 2018 Taylor & Francis Group, LLC.


Keywords

HCV; Hepatocellular Carcinoma; miRNAs; Carcinoma, Hepatocellular; Circulating MicroRNA; Egypt; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Liver Neoplasms; Male; Middle Aged; alanine aminotransferase; albumin; alkaline phosphatase; alpha fetoprotein; aspartate aminotransferase; microRNA; microRNA 139; microRNA 145; microRNA 16; microRNA 199a; microRNA 221; microRNA 34a; prothrombin; unclassified drug; alanine aminotransferase blood level; albumin blood level; alkaline phosphatase blood level; alpha fetoprotein blood level; Article; aspartate aminotransferase blood level; cancer diagnosis; chronic hepatitis C; clinical feature; controlled study; diagnostic value; early diagnosis; gene expression; genotype; Hepatitis C virus; human; liver; liver cell carcinoma; liver cirrhosis; major clinical study; non invasive measurement; real time polymerase chain reaction; sensitivity and specificity; blood; genetics; isolation and purification; liver tumor; pathology; virology


Citation Information

Scopus Citations: 30


For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.

The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.

English Website: https://www.tbri.sci.eg/en/

Arabic Website: https://www.tbri.sci.eg/ar/

Prepared and Uploaded by:

Abdalla F. Abdalla

Electronic Portal Unit

Electronic Portal Unit

Popular Posts

A cost-performance index for nano-optical biosensor evaluation: Systematic evaluation of europium–salicylate luminescent platforms for GPC3-targeted early HCC diagnosis

Interpretation of liver stiffness measurement in patients with mixed liver disease etiologies

Variable clinical presentations of pulmonary hydatid cysts: a four-case series from a single center in United Arab Emirates, non-endemic region

Holothuria arenicola Extract-Loaded Polycaprolactone Nanocapsules Attenuate Bile Duct Ligation-Induced Acute Liver Injury

Mytilus edulis-mediated green synthesis of selenium nanoparticles with antimicrobial and molluscicidal applications

Corrigendum to ‘Eco-friendly approach for the removal and simultaneous detection of cyanide toxins from drinking and wastewater sources’ [Environ. Pollut. 385 (2025) 127094]

Multifunctional polycaprolactone-based composite fibers with icariin and glutathione for effective repair of critical-sized bone defects